| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Research and development | 2,964 | 1,750 | 3,045 | 4,868 |
| General and administrative | 4,378 | 5,213 | 3,206 | 2,533 |
| Total operating expenses | 7,342 | 6,963 | 6,251 | 7,401 |
| Loss from operations | -7,342 | -6,963 | -6,251 | -7,401 |
| Interest income | 279 | 155 | 416 | 462 |
| Interest expense | 15 | 13 | 15 | 16 |
| Change in fair value of warrant liability | -1,067 | -374 | -1,754 | -16,810 |
| Total other income (expenses) | 1,331 | 516 | 2,155 | 17,256 |
| Net loss | -6,011 | -6,447 | -4,096 | 9,855 |
| Dividend to series b-1 preferred stockholders | - | 0 | - | 887 |
| Net incomeloss attributable to participating securities | - | - | - | -5,925 |
| Net income attributable to participating securities | - | 0 | - | - |
| Net loss attributable to common stockholders | -6,011 | -6,447 | -4,096 | 3,043 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.33 | -0.52 | -0.05 | 0.08 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.33 | -0.52 | -0.05 | -0.15 |
| Weighted-average shares outstanding used in computing net loss per share, basic (in shares) | 18,065,389 | 12,302,059 | 88,943,212 | 37,914,812 |
| Weighted-average shares outstanding used in computing net loss per share,diluted (in shares) | 18,065,389 | 12,302,059 | 88,943,212 | 94,052,853 |
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)